Homology Medicines to Participate in Upcoming Conferences
Homology Medicines, Inc. (Nasdaq: FIXX) announced its participation in several upcoming virtual conferences. Key events include a fireside chat at the Oppenheimer Fall Healthcare Summit on September 22 and another at the Chardan 4th Annual Genetic Medicines Conference on October 5. Additionally, the company will present on-demand sessions at the Cell & Gene Meeting on the Mesa on October 12 and 15. Webcasts of these presentations will be accessible on their website for 90 days post-event. Homology is focused on delivering genetic medicines for rare diseases using advanced technology.
- None.
- None.
BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences:
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
o Fireside Chat: September 22 at 4:10 p.m. ET - Chardan 4th Annual Genetic Medicines Conference
o Fireside Chat: October 5 at 11:30 a.m. ET - Cell & Gene Meeting on the Mesa
o Corporate presentation: Available on-demand October 12
o Panel presentation, “Accelerating Biotherapeutic Development and Production for Increased Market Impact of Life-Saving Therapeutics”: Available on-demand October 12
o Panel presentation, “Cell and Gene Therapy Portfolio Strategy”: Available on-demand October 15
The live webcast presentations from the Oppenheimer and Chardan conferences will be accessible on Homology’s website in the Investors section, and the webcast replays will be available on the website for 90 days following the presentations. For on-demand webcasts from the Cell & Gene Meeting on the Mesa conference, please visit www.meetingonthemesa.com for full information.
About Homology Medicines, Inc.
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit www.homologymedicines.com.
| Company Contacts: | |
| Theresa McNeely | |
| Chief Communications Officer and Patient Advocate | |
| tmcneely@homologymedicines.com | |
| 781-301-7277 | |
| Media Contact: | |
| Cara Mayfield | |
| Senior Director, Patient Advocacy and Corporate Communications | |
| cmayfield@homologymedicines.com | |
| 781-691-3510 |
FAQ
What conferences is Homology Medicines participating in September 2020?
When will the Cell & Gene Meeting on the Mesa presentations be available?
Are the webcasts from the conferences accessible to the public?
What is the focus of Homology Medicines?
What is the stock symbol for Homology Medicines?
